Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients with Burn Wound Sepsis

Journal of Burn Care and Research

Volumn 36, Issue 4, 2015, Pages e244-e252

  Yu, Tian ^a   Stockmann, Chris ^a   Healy, Daniel P ^b,c   Olson, Jared ^d   Wead, Stephanie ^b   Neely, Alice N ^c   Kagan, Richard J ^c,e   Spigarelli, Michael G ^a   Sherwin, Catherine M T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN   (United States)

^d PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ARTICLE; BACTERICIDAL ACTIVITY; BURN INFECTION; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; SEPSIS; VOLUME OF DISTRIBUTION; BODY WEIGHT; BURN; COMPLICATION; DOSE RESPONSE; STATISTICAL MODEL;

AMIKACIN; ANTI-BACTERIAL AGENTS; BODY WEIGHT; BURNS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, STATISTICAL; SEPSIS;

EID: 84937574099     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0000000000000159     Document Type: Article

References (27)

1. Rex S. Burn injuries. Curr Opin Crit Care 2012;18:671-6.
2. Krishnan P, Frew Q, Green A, Martin R, Dziewulski P. Cause of death and correlation with autopsy findings in burns patients. Burns 2013;39(4):583-8. doi:10.1016/j.burns.2012.09.017
3. Bone RC. Gram-negative sepsis. Background, clinical features, and intervention. Chest 1991;100:802-8.
4. Orban C, Tomescu D. The importance of early diagnosis of sepsis in severe burned patients: outcomes of 100 patients. Chirurgia (Bucur) 2013;108:385-8.
5. Tally FP, Louie TJ, Weinstein WM, Bartlett JG, Gorbach SL. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms. Ann Intern Med 1975;83:484-8.
6. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10; quiz 11-2.
7. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1; 2013.
8. Gálvez R, Luengo C, Cornejo R, et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011;38:146-51.
9. Conil JM, Georges B, Breden A, et al. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 2006;28:226-30.
10. Greenhalgh DG, Saffle JR, Holmes JH 4th, et al; American Burn Association Consensus Conference on Burn Sepsis and Infection Group. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res 2007;28:776-90.
11. Sherwin CM, Wead S, Stockmann C, et al. Amikacin population pharmacokinetics among paediatric burn patients. Burns 2014;40:311-8.
12. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009;24:25-36.
13. Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet 2012;51:573-90.
14. Williams FN, Herndon DN, Hawkins HK, et al. The leading causes of death after burn injury in a single pediatric burn center. Crit Care 2009;13:R183.
15. Sharma BR, Harish D, Singh VP, Bangar S. Septicemia as a cause of death in burns: an autopsy study. Burns 2006;32:545-9.
16. Luterman A, Dacso CC, Curreri PW. Infections in burn patients. Am J Med 1986;81(1A):45-52.
17. Zhang LH, Wang LF, Meng ZY, et al. [Optimization of antibiotics in combination]. Zhonghua Shao Shang Za Zhi 2008;24:93-6.
18. Kopcha RG, Fant WK, Warden GD. Increased dosing requirements for amikacin in burned children. J Antimicrob Chemother 1991;28:747-52.
19. Akers KS, Cota JM, Frei CR, Chung KK, Mende K, Murray CK. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother 2011;55:4639-42.
20. Romano S, Fdez de Gatta MM, Calvo MV, Caballero D, Dominguez-Gil A, Lanao JM. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 1999;44:235-42.
21. Fernandez de Gatta MM, Mendez ME, Romano S, Calvo MV, Dominguez-Gil A, Lanao JM. Pharmacokinetics of amikacin in intensive care unit patients. J Clin Pharm Ther 1996;21:417-21.
22. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999;44:319-27.
23. Boucher BA, Kuhl DA, Hickerson WL. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 1992;14:458-63.
24. Jaehde U, Sörgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995;29:15-28.
25. Yang RH, Rong XZ, Hua R, Zhang T. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn. Burns 2009;35:75-9.
26. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005;44:1009-34.
27. Layeux B, Taccone FS, Fagnoul D, Vincent JL, Jacobs F. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010;54:4939-41.